Company
GlycoMar (founded in 2005) is a biotechnology company, with expertise in the discovery and development of high value polysaccharide and carbohydrate products for pharmaceutical, personal care and nutrition sectors.
Over a ten year period the company established a discovery platform technology for the identification and biological evaluation of glycobiology products.
GlycoMar has successfully worked with a wide range of commercial partners from Pharma to food. We have successfully supported the development of novel personal care ingredients, including PrasinoGuard which is being commercialised by MicroA in Norway, with continued support from GlycoMar.
GlycoMar has a unique combination of expertise in glycobiology and polysaccharide isolation from natural sources, especially the marine environment. We combine this extensive biochemical and bioindustrial knowledge with experience in the evaluation of saccharide bioactivity, such as immunomodulatory properties.
GlycoMar offers this unique combination of skills as consultancy to commercial and academic partners, seeking to develop new glycobiology products or solve technical problems.
People
GlycoMar's team has decades experience in marine biotechnology and drug discovery & development, providing the depth and breadth of knowledge and experience required to innovate effectively.
Management & Board
Dr Mike Wyllie, Ph.D., DSc., Chairman & Non-executive Director
Dr Wyllie has over 30 years of experience in senior management positions in the pharmaceutical industry. He is a director and founder of Global Pharma Consulting and is a graduate of the University of Aberdeen. While Director of Biology at Pfizer, he was involved in the discovery, development, regulatory filing and marketing of eight major pharmaceutical products including amlodipine (Norvasc) doxazosin (Cardura), darifenacin (Enablex), fluconazole (Diflucan), sertraline (Zoloft) and sildenafil (Viagra). Subsequently, Dr Wyllie has been involved in founding several start-up companies and the successful listing of four of these on the London Stock Market. He is founder and Chief Scientific Officer of Plethora Solutions, Plc, which has a product, PSD502 (Fortacin), approved in the EU for premature ejaculation and undergoing regulatory review by the FDA. He is Chairman of Morvus Ltd, the oncology company and is a non-executive director of Repros Therapeutics the NASDAQ-listed development stage biopharmaceutical company in Houston.
Mr John Whitehead, OBE, Non-executive Director
John has many years experience in food production and processing, latterly as Managing Director of Dundee food manufacturers Top Hat Holdings Ltd. He is the immediate past Chairman of Seafish, a founder Director of the Food & Drink Exporters Association, and a Director of Improve, the Sector Skills Council for Food & Drink. He currently chairs the Certification Council of Scottish Food Quality Certification Ltd and holds non-executive appointments with Strathmore Foods Ltd and Gourmet's Choice Ltd.